Macau, Hengqin create fast-track channel for innovative TCM


Under a new cross-border cooperation agreement, Macau and Hengqin pharmaceutical regulators have created a coordinated channel to help modern traditional Chinese medicines developed in Hengqin secure registration and enter the Macau market.
The Pharmaceutical Administration Bureau of Macau (ISAF) and the Commercial Affairs Bureau of the Guangdong-Macao In-Depth Cooperation Zone in Hengqin signed the memorandum on Monday, with ISAF president Choi Peng Cheong and Zhang Wenji, director of Hengqin’s Commercial Affairs Bureau, signing on behalf of the two sides.
According to ISAF’s announcement, the arrangement is intended to bring Macau regulators into the development process earlier, providing targeted support to companies navigating application procedures, technical requirements and documentation standards before filing for registration.
For products that both regulators determine to meet urgent clinical needs, the agencies may provide support throughout the product life cycle, from pharmaceutical and preclinical research through clinical trials, registration, evaluation, approval and the initial post-marketing period, ISAF said.
Under the “Hengqin research and development + Macau registration” model, Hengqin-developed medicines may enter the new channel after an initial assessment and recommendation by Hengqin authorities, followed by review and confirmation by ISAF.
ISAF will provide guidance during the research and development stage on registration procedures, technical requirements and information standards for Macau.
On strengthening coordination between Macau and Hengqin, Choi said the agreement would help bring more high-quality, innovative traditional Chinese medicines developed on the mainland into Macau. According to ISAF, the initiative will also help companies make fuller use of the Hengqin-Macau platform while supporting Macau’s economic diversification agenda.
Zhang described the arrangement as an “innovative and emblematic initiative,” saying it would build on Hengqin’s pharmaceutical industry cluster and strengthen cooperation between the two jurisdictions in the development and commercialization of traditional Chinese medicines.
The memorandum expands on an earlier framework that allowed selected Macau-registered medicines to be used in Hengqin. The new channel reverses that flow by helping products developed in the cooperation zone seek registration and market access in Macau.
The agencies said they would continue to refine cooperation mechanisms and advance a “Macau registration + Hengqin production + overseas sales” model.
Leave a reply
You must be logged in to post a comment.
























